Mural Oncology (NASDAQ:MURA) Now Covered by Rodman & Renshaw

Equities researchers at Rodman & Renshaw began coverage on shares of Mural Oncology (NASDAQ:MURA) in a research note issued to investors on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. Rodman & Renshaw’s price target suggests a potential upside of 388.60% from the stock’s current price.

Separately, Morgan Stanley assumed coverage on shares of Mural Oncology in a research report on Thursday, April 4th. They set an “overweight” rating and a $13.00 price target for the company.

Mural Oncology Stock Performance

Shares of Mural Oncology stock opened at $3.07 on Friday. Mural Oncology has a 1 year low of $3.05 and a 1 year high of $17.00. The firm’s 50-day moving average is $3.53 and its two-hundred day moving average is $4.28.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, May 14th. The company reported ($1.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.66) by $0.82. Equities analysts expect that Mural Oncology will post -7.54 EPS for the current fiscal year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.